Regulatory perspectives increasingly emphasize the value of integrating modeling early in the drug development process rather than applying it retrospectively. Early model development enables a more structured, hypothesis-driven approach to data generation and decision-making, ultimately increasing confidence in model-informed strategies.
When models are introduced early, they become tools for learning and planning, not just for confirmation. This allows teams to proactively shape development rather than react to data after the fact.
If you are still utilizing modeling at later stages of development, you may want to consider a shift—and in this blog post, we’ll explain why.
Key benefits of early integration
Leading pharma companies are expanding their use of modeling and simulation, and there are five main reasons.
- Guiding data collection aligned with key decisions
Models help define what data are needed to answer critical questions (e.g., dose selection, exposure-response), ensuring studies are designed to be decision-relevant rather than exploratory. - Enabling iterative model refinement as new data emerge
As additional data become available, models can be continuously updated, improving their predictive performance and reducing uncertainty over time. - Identifying knowledge gaps early in development
Early modeling highlights limitations and gaps in understanding (e.g., insufficient covariate coverage, lack of exposure range, uncertainty in target distribution and/or expression), allowing focused data collection before pivotal studies. - Reducing uncertainty before key decision points
Through iterative model refinement, uncertainty can be more systematically characterized, quantified, and reduced ahead of high-impact decisions such as Phase III trial design, labeling strategies, and biowaiver determinations. This process enables more informed decision making by explicitly evaluating how assumptions, variability, and data limitations (e.g., fit-for-purpose data) influence predicted outcomes. - Strengthening overall program confidence and regulatory credibility
A prospectively integrated modeling strategy demonstrates a systematic and scientifically grounded approach, which aligns with regulatory expectations for model-informed drug development.
Model risk and model impact in a regulatory context
Regulatory evaluation of models increasingly incorporates a risk-based framework that considers both model risk, the potential for incorrect or misleading decisions due to model limitations, and model impact, the extent to which the model influences a regulatory or clinical decision.
Model risk arises from multiple sources, including structural assumptions, data limitations, parameter uncertainty, and extrapolation beyond observed data. Importantly, risk is not only about whether a model is “correct,” but about the consequences of being wrong. A model used to explore hypotheses carries relatively low risk, whereas a model directly informing dosing, labeling, or waiving clinical studies carries substantially higher risk. Notably, these two are not mutually exclusive, where model exploration of hypotheses may be the only “direct” mode of addressing the impact of the hypotheses on critical decisions. In these more complex settings, the need for an integrated weight-of-evidence approach is paramount.
Model impact, in contrast, reflects how heavily . Models may play a supportive role (e.g., contextualizing results) or serve as primary evidence (e.g., dose justification, pediatric extrapolation, or biowaiver decisions). As model impact increases, so does the expectation for rigor.
Regulatory expectations scale with the combination of risk and impact:
- Low-impact / low-risk models may require standard documentation and basic evaluation.
- High-impact / high-risk models require more extensive documentation, including clear language interpreting the simulation results and the limitations of the interpretation, sensitivity analyses, and evaluation of alternative assumptions.
High-impact and high-risk models demand the highest level of transparency, reproducibility, and credibility, often including multiple lines of evidence to support conclusions.
In practice, this means that model evaluation is not one-size-fits-all. Instead, the level of validation, documentation, and scrutiny should be proportionate to how the model will be used and the potential consequences of incorrect decisions.
Case study: dose selection and model risk
A sponsor submitted a population PK/PD model to support dose reduction for an oncology therapy. The model was intended to directly inform labeling, positioning it as a high-impact application, where model outputs would serve as primary evidence for a regulatory decision.
During initial review, several concerns were identified. Dataset derivations were not fully traceable to source data, covariate inclusion lacked clear biological or clinical justification, and sensitivity analyses, particularly around key assumptions such as BLQ handling, were limited. While the model demonstrated reasonable statistical performance, these gaps reduced transparency and hindered reproducibility.
Given the model’s high impact, these limitations translated into elevated model risk. From a regulatory perspective, insufficient traceability and lack of robustness testing raised concerns about whether the proposed dose reduction was reliably supported and whether alternative assumptions could materially change the conclusions.
To address these issues, the sponsor revised the submission by strengthening both transparency and model evaluation in a manner aligned with the model’s impact:
- Providing fully traceable datasets
All analysis datasets were clearly linked to source data, with documented derivations enabling independent reconstruction.
- Enhancing reproducibility with executable workflows
Model code, scripts, and run instructions were standardized and fully executable, allowing reviewers to reproduce key analyses without ambiguity.
- Adding sensitivity analyses for key assumptions
Alternative approaches to BLQ handling, covariate inclusion, and structural assumptions were evaluated and reported to demonstrate the robustness of conclusions.
- Demonstrating robustness under alternative scenarios
Simulations were expanded to show that the proposed dosing strategy remained valid across plausible ranges of uncertainty. These enhancements allowed reviewers to independently run the analysis and assess the solidity of conclusions under different assumptions. As a result, perceived model risk was substantially reduced, and confidence in the model increased. Ultimately, the model was accepted as credible evidence to support the dosing strategy. Importantly, the underlying model did not fundamentally change; the key shift was in transparency, reproducibility, and alignment of evaluation with model impact.
Transparent modeling is essential for managing model risk and supporting high-impact regulatory decisions. When transparency, reproducibility, and scientific justification are aligned with model impact, confidence in model-informed decisions increases significantly. Organizations that integrate modeling early, document thoroughly, and align validation with risk are better positioned for efficient regulatory review and successful outcomes.
If you’d like support with your regulatory strategy, schedule a 15-minute call with our experts.